Contineum Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview

Contineum Therapeutics

31/07/2026 12:01

Contineum Therapeutics Inc CTNM.OQ CTNM.O is expected to  show a rise in quarterly revenue when it reports  results on October 28 (estimated) for the period ending September 30 2026
The San Diego California-based  company is expected to report revenue of $3.767 million, according to the mean estimate from 3 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Contineum Therapeutics Inc is for a loss of 42 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts had risen by about 18.9% in the last three months. ​
Wall Street's median 12-month price target for Contineum Therapeutics Inc is $23.00, about 46% above its last closing price of $15.75
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2026
-0.45
-0.45
-0.40
Beat
11.4
Mar. 31 2026
-0.55
-0.53
-0.39
Beat
26.6
Dec. 31 2025
-0.54
-0.41
-0.49
Missed
-20.8​
Sep. 30 2025
-0.61
-0.48
-0.45
Beat
7
​​Jun. 30 2025
-0.54
-0.44
-0.62
Missed
-40.9
Mar. 31 2025
-0.57
-0.56
-0.62
Missed
-9.7​
Dec. 31 2024
-0.44
-0.43
-0.56
Missed
-30.8
Sep. 30 2024
-0.41
-0.41
-0.40
Beat
2.4
This summary was machine generated July 31 at 11:01 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)